| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
26,062 |
25,378 |
$1.26M |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
12,968 |
12,555 |
$642K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,897 |
6,724 |
$504K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
5,771 |
5,591 |
$448K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
10,814 |
10,455 |
$311K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,696 |
2,634 |
$203K |
| 87634 |
|
429 |
377 |
$20K |
| 71046 |
Radiologic examination, chest; 2 views |
691 |
676 |
$12K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
28 |
26 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
135 |
116 |
$2K |
| 81003 |
|
597 |
581 |
$1K |
| 74018 |
|
63 |
62 |
$1K |
| 69210 |
|
13 |
13 |
$573.45 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
412 |
398 |
$263.15 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
321 |
229 |
$201.43 |
| 94761 |
|
100 |
92 |
$161.55 |
| 82947 |
|
32 |
30 |
$110.30 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
147 |
101 |
$29.64 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
65 |
52 |
$11.41 |